Marinus Pharmaceuticals Valuation
Is 61Y undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 61Y when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 61Y (€0.28) is trading below our estimate of fair value (€187.86)
Significantly Below Fair Value: 61Y is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 61Y?
Key metric: As 61Y is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is 61Y's PS Ratio? | |
|---|---|
| PS Ratio | 0.5x |
| Sales | US$31.47m |
| Market Cap | US$16.97m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.7x |
| Enterprise Value/EBITDA | -0.4x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 61Y's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 12.6x | ||
B8FK Biofrontera | 0.8x | n/a | €17.0m |
SBX SynBiotic | 7.8x | 39.7% | €29.9m |
0RX Redx Pharma | 13.3x | -37.6% | €65.0m |
HIGH Cantourage Group | 28.6x | 38.6% | €56.1m |
61Y Marinus Pharmaceuticals | 0.5x | 34.9% | €17.0m |
Price-To-Sales vs Peers: 61Y is good value based on its Price-To-Sales Ratio (0.5x) compared to the peer average (12.6x).
Price to Sales Ratio vs Industry
How does 61Y's PS Ratio compare vs other companies in the European Pharmaceuticals Industry?
Price-To-Sales vs Industry: 61Y is good value based on its Price-To-Sales Ratio (0.5x) compared to the European Pharmaceuticals industry average (3.1x).
Price to Sales Ratio vs Fair Ratio
What is 61Y's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.5x |
| Fair PS Ratio | 0.5x |
Price-To-Sales vs Fair Ratio: 61Y is expensive based on its Price-To-Sales Ratio (0.5x) compared to the estimated Fair Price-To-Sales Ratio (0.5x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €0.28 | €1.40 +391.2% | 64.9% | €2.85 | €0.29 | n/a | 6 |
| Nov ’25 | €0.27 | €1.72 +532.5% | 65.5% | €3.71 | €0.46 | n/a | 7 |
| Oct ’25 | €1.52 | €7.63 +402.2% | 72.0% | €20.66 | €1.80 | n/a | 10 |
| Sep ’25 | €1.22 | €6.35 +420.9% | 59.8% | €11.80 | €1.82 | n/a | 8 |
| Aug ’25 | €1.25 | €6.21 +397.0% | 60.8% | €12.11 | €1.86 | n/a | 9 |
| Jul ’25 | €1.04 | €6.21 +497.3% | 60.8% | €12.11 | €1.86 | n/a | 9 |
| Jun ’25 | €1.41 | €6.20 +340.0% | 60.8% | €12.10 | €1.86 | n/a | 9 |
| May ’25 | €1.28 | €8.23 +542.7% | 86.4% | €25.30 | €1.87 | n/a | 9 |
| Apr ’25 | €8.05 | €18.75 +132.9% | 29.2% | €25.86 | €8.31 | n/a | 10 |
| Mar ’25 | €8.65 | €18.59 +114.9% | 29.2% | €25.64 | €8.24 | n/a | 10 |
| Feb ’25 | €8.85 | €18.59 +110.1% | 29.2% | €25.64 | €8.24 | n/a | 10 |
| Jan ’25 | €9.75 | €18.68 +91.5% | 29.1% | €26.15 | €8.40 | n/a | 10 |
| Dec ’24 | €6.10 | €18.68 +206.2% | 29.1% | €26.15 | €8.40 | n/a | 10 |
| Nov ’24 | €6.45 | €19.61 +204.0% | 31.2% | €30.02 | €8.44 | €0.27 | 10 |
| Oct ’24 | €7.65 | €19.61 +156.3% | 31.2% | €30.02 | €8.44 | €1.52 | 10 |
| Sep ’24 | €6.45 | €18.82 +191.8% | 32.7% | €29.23 | €8.22 | €1.22 | 10 |
| Aug ’24 | €9.95 | €21.75 +118.5% | 31.3% | €38.70 | €12.90 | €1.25 | 10 |
| Jul ’24 | €9.30 | €21.75 +133.8% | 31.3% | €38.70 | €12.90 | €1.04 | 10 |
| Jun ’24 | €6.55 | €21.75 +232.0% | 31.3% | €38.70 | €12.90 | €1.41 | 10 |
| May ’24 | €7.45 | €22.33 +199.8% | 38.6% | €45.58 | €12.76 | €1.28 | 10 |
| Apr ’24 | €6.30 | €23.04 +265.7% | 39.9% | €47.41 | €11.38 | €8.05 | 10 |
| Mar ’24 | €6.40 | €22.55 +252.3% | 39.2% | €46.02 | €11.04 | €8.65 | 10 |
| Feb ’24 | €5.75 | €22.55 +292.1% | 39.2% | €46.02 | €11.04 | €8.85 | 10 |
| Jan ’24 | €3.50 | €25.08 +616.7% | 40.3% | €49.95 | €11.99 | €9.75 | 9 |
| Dec ’23 | €4.50 | €25.08 +457.4% | 40.3% | €49.95 | €11.99 | €6.10 | 9 |
| Nov ’23 | €5.70 | €28.58 +401.4% | 32.4% | €50.14 | €17.05 | €6.45 | 8 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
Teva Pharmaceutical Industries
US$18.7b
Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.
TEV
US$15.30
7D
-5.8%
1Y
75.1%
Fortrea Holdings
US$1.7b
A contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide.
K67
US$17.30
7D
-17.6%
1Y
-40.3%
Pharming Group
€481.3m
A biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.
PHGN
€0.71
7D
-3.5%
1Y
-34.8%